Literature DB >> 2300354

The role of peptide growth factors in epithelial ovarian cancer.

A Berchuck1, G J Olt, L Everitt, A P Soisson, R C Bast, C M Boyer.   

Abstract

We studied the effect of epidermal growth factor, platelet-derived growth factor, fibroblast growth factor, and transforming growth factor-beta on proliferation of four epithelial ovarian cancer cell lines (OVCA 420, OVCA 429, OVCA 432, and OVCA 433). Epidermal growth factor stimulated growth of OVCA 429 cells (P = .0001) and OVCA 433 cells (P = .0002). Platelet-derived growth factor did not stimulate growth of any of the cell lines. Fibroblast growth factor stimulated growth of OVCA 420 cells (P = .003). Transforming growth factor-beta inhibited growth of OVCA 420 cells (P = .0001), OVCA 432 cells (P = .003), and OVCA 433 cells (P = .004). To detect production of known growth factors by the cancer cell lines, we tested the effect of cancer cell-conditioned media on proliferation of cell lines known to respond to growth factors. Only media exposed to OVCA 433 cells were found to contain activity that mimicked one of the known growth factors (transforming growth factor-beta). These results suggest that individual ovarian cancers vary widely in their response to and production of known peptide growth factors. Finally, we found that OVCA 429-conditioned medium significantly inhibited proliferation of mitogen-stimulated lymphocytes (P less than .0001). The characteristics of this immunosuppressive factor were distinct from those of transforming growth factor-beta. Production of this factor by an immortalized cell line provides a unique opportunity to identify an immunosuppressive substance associated with ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2300354

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  7 in total

1.  RhoB mediates antitumor synergy of combined ixabepilone and sunitinib in human ovarian serous cancer.

Authors:  Prakash Vishnu; Gerardo Colon-Otero; Gregory T Kennedy; Laura A Marlow; William P Kennedy; Kevin J Wu; Joseph T Santoso; John A Copland
Journal:  Gynecol Oncol       Date:  2011-11-22       Impact factor: 5.482

2.  Growth stimulation of ovarian and extraovarian mesothelial cells by corpus luteum extract.

Authors:  S Setrakian; B Oliveros-Saunders; S V Nicosia
Journal:  In Vitro Cell Dev Biol Anim       Date:  1993-11       Impact factor: 2.416

Review 3.  Activated epidermal growth factor receptor in ovarian cancer.

Authors:  Laurie G Hudson; Reema Zeineldin; Melina Silberberg; M Sharon Stack
Journal:  Cancer Treat Res       Date:  2009

4.  Production of insulin-like growth factor binding proteins by human ovarian carcinoma cells.

Authors:  J Hofmann; B Wegmann; R Hackenberg; R Kunzmann; K D Schulz; K Havemann
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

Review 5.  Insulin-Sensitizers, Polycystic Ovary Syndrome and Gynaecological Cancer Risk.

Authors:  Rosa Lauretta; Giulia Lanzolla; Patrizia Vici; Luciano Mariani; Costanzo Moretti; Marialuisa Appetecchia
Journal:  Int J Endocrinol       Date:  2016-09-20       Impact factor: 3.257

6.  Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy.

Authors:  G Scambia; P Benedetti-Panici; G Ferrandina; M Distefano; G Salerno; M E Romanini; A Fagotti; S Mancuso
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

Review 7.  Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer.

Authors:  Maritza P Garrido; Allison N Fredes; Lorena Lobos-González; Manuel Valenzuela-Valderrama; Daniela B Vera; Carmen Romero
Journal:  Biomedicines       Date:  2021-12-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.